Diffuse Malignant Pleural Mesothelioma - Gemcitabine Treatment
References
Aisner J, Wiernik PH (1981) Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 8: 335-343
Alberts AS, Falkson G, Van Zyl L (1988) Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 80: 698-700
Andersen MK, Krarup-Hansen A, Martensson G, Winther-Nielsen H, Thylen A, Damgaard K, Olling S, Wallin J (1999) Ifosfamide in malignant mesothelioma: a phase II study. Lung Cancer 24: 39-43
Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP (1980) Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 68: 356-362
Antman KH, Corson JM. (1985) Benign and malignant pleural mesothelioma. Clin Chest Med 6: 127-140
Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M et al (1991) Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 67: 2984-2987
Aversa SL, Crcuri C, DePangher V et al (1998) Carboplatin and Gemcitabine chemotherapy for malignant pleural mesothelioma (Malignant Pleural Mesothelioma (MPM)): A phase II study of the GSTPV. Ann of Oncol 9: 117
Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G (2000) Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol 11: 697-700
Bajorin D, Kelsen D, Mintzer DM (1987) Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 71: 857-858
Bednar ME, Chahinian P (1999) Paclitaxel and carboplatin for malignant mesothelioma. Ann Meet Am Soc Clin Oncol A1916 18: 496a
Belani CP, Adak S, Aisner S, Stella PJ, Levitan N, Johnson DH (1999) Docetaxel for malignant mesothelioma: phase II study of the eastern Cooperative Oncology Group (ECOG 2595). Proc Am Soc Clin Oncol 1999 A1829, Vol 18, p.p. 474a
Bischoff HG, Manegold C, Knopp M, Blatter J, Drings P (1998) Gemcitabine (GemzarÒ) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Ann Meet Am Soc Clin Oncol 17; A1784
Bissett D, Macbeth FR, Cram I (1991) The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol) 3: 315-317
Boutin C, Irisson M, Guerin JC, Roegel E, Paramelle B, Brambilla C, Jeannin L, Dabouis G, Le Caer H, Viallat JR (1987) Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat Rep 71: 205-206
Boutin C, Schlesser M, Frenay C, Astoul P (1998) Malignant pleural mesothelioma. Eur Respir J 12: 972-981
Breau JL, Boaziz C, Morere JJF (1991) Cobination therapy with cisplatinum, adramycin, bleomycin and mitomycin C plus systemic and intra-pleural hyaluronidase in 25 consecitive cases of stages II, III pleural mesothelioma. Presented at the first International Mesothelioma Conference, Paris, France
Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BW (1999) Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17: 25-30 PubMed
Carmichael J, Cantwell BM, Harris AL (1989) A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. Eur J Cancer Clin Oncol 25: 911-912
Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon II JE, Aisner J, Ellison RR, Leone L et al. (1993) Randomised phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11: 1559-1565
Colbert N, Vannetzel JM, Izrael V, Schlienger M, Milleron B, Blanchon F, Herman D, Akoun G, Roland J, Chatelet F et al (1985) A prospective study of detorubicin in malignant mesothelioma. Cancer 56: 2170-2174
Cowan JD, Green S, Lucas J, Weick JK, Balcerzak SP, Rivkin SE, Coltman CA, Baker LH (1988) Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 6: 247-248
Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16: 145-152 PubMed
Dimitrov NV, Egner J, Balcueva E, Suhrland LG (1982) High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma. Cancer 50: 1245-1247
Dirix LY, van Meerbeeck J, Schrijvers D, Corthouts B, Prove A, van Marck E, Vermeire P, van Oosterom AT (1994) A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 5: 653-655
Eisenhauer EA, Evans WK, Murray N, Kocha W, Wierzbicki R, Wilson K (1988) A phase II study of VP-16 and cisplatin in patients with unresectable maignant mesothelioma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 6: 327-329
Eisenhauer EA, Evans WK, Raghavan D, Desmeules MJ, Murray NR, Stuart-Harris R, Wilson KS (1986) Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep 70: 1029-1030
Falkson G, Hunt M, Borden EC, Hayes JA, Falkson CI, Smith TJ (1992) An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 10: 337-343
Fizazi K, Caliandro R, Soulie P, Fandi A, Daniel C, Bedin A, Doubre H, Viala J, Rodier J, Trandafir L, Le Chevalier T, Cvitkovic E, Armand J, Ruffie P (2000) Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer 36: 1514-1521 PubMed
Giaccone G, O'Brien M, Byrne MJ, Van Steenkiste J, Cosaert J (2001) Phase II Trial of ZD0473 in Patients with Mesothelioma Relapsing After One Prior Chemotherapy Regimen. Proc Ann. Meet Am Soc Clin Oncol A2781 20: 257b
Gridelli C, Pepe R, Airoma G, Incoronato P, Rossi A, Palazzolo G, Bianco AR (1992) Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma. Tumori 78: 380-382
Harvey VJ, Slevin ML, Ponder BA, Blackshaw AJ, Wrigley PF (1984) Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 54: 961-964
Henss H, Fiebig HH, Schildge J, Arnold H, Hasse J (1988) Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11: 118-120
Hilaris BS, Nori D, Kwong E, Kutcher GJ, Martini N (1984) Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 10: 325-331
Hughes A, Calvert P, Azzabi A, Plummer A, Johnsons R, Rusthoven R, Griffin M, Fishwick K, Boddy AV, Verril M, Calvert H (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncology 20: 3533-3544
Icli F, Karaoguz H, Hasturk S, Kurt B, Akbulut H, Dincol D, Demirkazik A, Cay F, Akyar S (1996) Two dose levels of ifosfamide in malignant mesothelioma. Lung Cancer 15: 207-213
Kaukel E, Koschel G, Gatzemeyer U, Salewski E (1990) A phase II study of pirarubicin in malignant pleural mesothelioma. Cancer 66: 651-654
Kelsen D, Gralla R, Cheng E, Martini N (1983) Vindesine in the treatment of malignant mesothelioma: a phase II study. Cancer Treat Rep 67: 821-822
Kindler HL, Belani CP, Herndon II JE, Vogelzang NJ, Suzuki Y, Green MR (1999) Edatrexate (10-ethyl-deaza-aminopterin) (NSC # 626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer 86: 1985-1991
Kindler HL, Herndon JE, Vogelzang NJ, Green MR. (2000). CPT-11 in Malignant Mesothelioma: A Phase II Trial by the Cancer and Leukemia Group B (CALGB 9733). Proc Ann. Meet Am Soc Clin Oncol 27: A1978. Vol. 19, pp. 505a
Kindler HL, Millard F, Herndon II JE, Vogelzang NJ, Suzuki Y, Green MR (2001) Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31: 311-317 Article PubMed
Knuuttila A, Ollikainen T, Halme M, Mali P, Kivisaari L, Linnainmaa K, Jekunen A, Mattson K (2000) Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study. Anticancer Drugs 11: 257-261
Krarup-Hansen A (1996) Studies concerning high dose ifosfamide to patients suffering from malignant mesothelioma. Lung Cancer 16: 101-102
Kutcher GJ, Kestler C, Greenblatt D, Brenner H, Hilaris BS, Nori D (1987) Technique for external beam treatment for mesothelioma. Int J Radiat Oncol Biol Phys 13: 1747-1752
Linden CJ, Mercke C, Albrechtsson U, Johansson L, Ewers SB (1996) Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomised phase II study. Eur Respir J 9: 2565-2572
Magri MD, Foladore S, Veronesi A, Serra C, Nicotra M, Tommasi M, Grandi G, Monfardini S, Bianchi C (1992) Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. Ann Oncol 3: 237-238
Magri MD, Veronesi A, Foladore S, De Giovanni D, Serra C, Crismancich F, Tuveri G, Nicotra M, Tommasi M, Morassut S et al (1991) Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)--Mesothelioma Committee. Tumori 77: 49-51
Maksymiuk AW, Marschke Jr RF, Tazelaar HD, Grill J, Nair S, Marks RS, Brooks BJ, Mailliard JA, Burton GM, Jett JR (1998) Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 21: 610-613
Martensson G, Sorenson S (1989) A phase II study of vincristine in malignant mesothelioma--a negative report. Cancer Chemother Pharmacol 24: 133-134
Mattson K, Giaccone G, Kirkpatrick A, Evrard D, Tammilehto L, van Breukelen FJ, Planteydt HT, van Zandwijk N (1992) Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 10: 824-828
Mbidde EK, Harland SJ, Calvert AH, Smith IE (1986) Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 18: 284-285
Middleton GW, Smith IE, O'Brien ME, Norton A, Hickish T, Priest K, Spencer L, Ashley S. (1998) Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9: 269-273 PubMed
Nakano T, Chahinian AP, Shinjo M, Togawa N, Tonomura A, Miyake M, Ninomiya K, Yamamoto T, Higashino K (1999) Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 85: 2375-2384
Novak A, Byrne M, Williamson R (2002) Multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87: 491-496 Article
Oh Y, Perez-Soler R, Fossella FV, Glisson BS, Kurie J, Walsh GL, Truong M, Shin DM (2000) Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 18: 243-245
Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR (1998) Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 115: 310-317 discussion 317-318
Pennucci MC, Ardizzoni A, Pronzato P, Fioretti M, Lanfranco C, Verna A, Giorgi G, Vigani A, Frola C, Rosso R (1997) Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force. Cancer 79: 1897-1902
Pinto C, Marino A, Guaraldi M, Melotti B, Piana E, Martoni A, Pannuti F (2001) Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 24(2): 143-147
Planting AS, van der Burg ME, Goey SH, Schellens JH, van den Bent MJ, de Boer-Dennert M, Stoter G, Verweij J (1995) Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 6: 613-615
Raghavan D, Gianoutsos P, Bishop J, Lee J, Young I, Corte P, Bye P, McCaughan B (1990) Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8: 151-154
Rusch VW, Venkatraman E (1996) The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 111: 815-825 discussion 825-826
Sahmoud T, Postmus PE, van Pottelsberghe C, Mattson K, Tammilehto L, Splinter TA, Planting AS, Sutedja T, van Pawel J, van Zandwijk N, Baas P, Roozendaal KJ, Schrijver M, Kirkpatrick A, Van Glabbeke M, Ardizzoni A, Giaccone G (1997) Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 33: 2211-2215 PubMed
Samson MK, Wasser LP, Borden EC, Wanebo HJ, Creech RH, Phillips M, Baker LH (1987) Randomised comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 5: 86-91
Samuels BL, Herndon II JE, Harmon DC, Carey R, Aisner J, Corson JM, Suzuki Y, Green MR, Vogelzang NJ (1998) Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer 82: 1578-1584
Scagliotti G, Shin D, Kindler H, Johnson D, Keppler U (2001) Phase II Study of ALIMTA (pemetrexed disodium, MTA) Single Agent in Patients with Malignant Pleural Mesothelioma. Eur J Cancer 37(Suppl. 6): 20
Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki R, McMurtrey MJ, Hong WK (1995) Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 76: 2230-2236
Solheim OP, Saeter G, Finnanger AM, Stenwig AE (1992) High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65: 956-960
Sorensen PG, Bach F, Bork E, Hansen HH (1985) Randomised trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69: 1431-1432
Soubra M, Dunscombe PB, Hodson DI, Wong G (1990) Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 18: 1521-1527
Sridhar KS, Hussein AM, Feun LG, Zubrod CG (1989) Activity of pirarubicin (4'-0-tetrahydropyranyladriamycin) in malignant mesothelioma. Cancer, 63: 1084-1091
Steele JP, O'Doherty CA, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM (2001) Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 12: 497-499
Steele JP, Rudd RM (2000) Malignant mesothelioma: predictors of prognosis and clinical trials. Thorax 55: 725-726
Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18: 3912-3917 PubMed
Tammilehto L, Maasilta P, Mantyla M, Salo J, Mattson K (1994) Oral etoposide in the treatment of malignant mesothelioma. A phase II study. Ann Oncol 5: 949-950
Thodtmann R, Depenbrock H, Blatter J, Johnson RD, van Oosterom A, Hanauske AR (1999) Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors. Semin Oncol 26: 89-93 PubMed
Tsavaris N, Mylonakis N, Karvounis N, Bacoyiannis C, Briasoulis E, Skarlos D, Pavlidis N, Stamatelos G, Kosmidis P (1994) Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 11: 299-303
van Breukelen FJ, Mattson K, Giaccone G, van Zandwijk N, Planteydt HT, Kirkpatrick A, Dalesio O (1991) Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 27: 1627-1629
Van Haarst JW, Burgers JA, Manegold CH et al. (2000) Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (Malignant Pleural Mesothelioma (MPM)). Program and abstracts of the 9th World Conference on Lung Cancer; September 11-15, Tokyo, Japan. Abstract 56
van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A, Gridelli C, van Marck EA, Lentz M, Giaccone G (1999) A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 85: 2577-2582 PubMed
van Meerbeeck J, Debruyne C, van Zandwijk N, Postmus PE, Pennucci MC, van Breukelen F, Galdermans D, Groen H, Pinson P, van Glabbeke M, van Marck E, Giaccone G (1996) Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 74: 961-963
Verschraegen C, Le D, Kudelka A, Kavanagh J, Hunt K (2001) Cisplatin and Irinotecan (CPT-11) for Peritoneal Mesothelioma. Proc Ann Meet Am Soc Clin Oncol A2110 20: 90
Vogelzang NJ, Goutsou M, Corson JM, Suzuki Y, Graziano S, Aisner J, Cooper MR, Coughlin KM, Green MR (1990) Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 27: 239-242
Vogelzang NJ, Herndon II JE, Cirrincione C, Harmon DC, Antman KH, Corson JM, Suzuki Y, Citron ML, Green MR (1997) Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 79: 2237-2242
Vogelzang NJ, Herndon II JE, Miller A, Strauss G, Clamon G, Stewart FM, Aisner J, Lyss A, Cooper MR, Suzuki Y, Green MR (1999) High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 10: 597-600
Vogelzang NJ, Weissman LB, Herndon II JE, Antman KH, Cooper MR, Corson JM, Green MR (1994) Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol 12: 1436-1442
Vorobiof DA, Chasen MR, Abratt R, Rapoport B, Cronje N, Fourie L, McMichael G, Hacking D (2000) Taxotere in malignant pleural mesothelioma. A Phase II clinical trial. Program and abstracts of the 9th World Conference on Lung Cancer; September 11-15, Tokyo, Japan. Abstract 58.
White SC, Anderson H, Jayson GC, Ashcroft L, Ranson M, Thatcher N (2000) Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in dvanced non-small-cell lung cancer and mesothelioma. Ann Oncol 11: 201-206
Zidar BL, Benjamin RS, Frank J, Lane M, Baker LH (1983) Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: a Southwest Oncology Group Study. Am J Clin Oncol 6: 71-74
Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L (1988) A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 6: 223-226 PubMed
Zidar BL, Metch B, Balcerzak SP, Pierce HI, Militello L, Keppen MD, Berenberg JL (1992) A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. Cancer 70: 2547-2551